|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HPSE2 |
Gene summary for HPSE2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HPSE2 | Gene ID | 60495 |
| Gene name | heparanase 2 (inactive) | |
| Gene Alias | HPA2 | |
| Cytomap | 10q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0006022 | UniProtAcc | Q8WWQ2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 60495 | HPSE2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.31e-02 | 8.55e-02 | 0.0155 |
| 60495 | HPSE2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 9.98e-05 | 2.00e-01 | -0.1808 |
| 60495 | HPSE2 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.38e-07 | 1.81e-01 | -0.1954 |
| 60495 | HPSE2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.09e-09 | 2.05e-01 | -0.059 |
| 60495 | HPSE2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 6.53e-42 | 1.40e+00 | 0.0338 |
| 60495 | HPSE2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.10e-02 | 1.70e-01 | 0.281 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Cervix | N_HPV |  |
| Endometrium | AEH |  |
| Endometrium | EEC |  |
| Prostate | BPH |  |
| Prostate | Tumor |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05205 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
| hsa052051 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
| hsa052052 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
| hsa052053 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
| hsa052054 | Colorectum | MSS | Proteoglycans in cancer | 65/1875 | 205/8465 | 8.66e-04 | 5.38e-03 | 3.29e-03 | 65 |
| hsa052055 | Colorectum | MSS | Proteoglycans in cancer | 65/1875 | 205/8465 | 8.66e-04 | 5.38e-03 | 3.29e-03 | 65 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HPSE2 | SNV | Missense_Mutation | c.767N>G | p.Ser256Cys | p.S256C | Q8WWQ2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HPSE2 | SNV | Missense_Mutation | novel | c.746N>A | p.Ala249Asp | p.A249D | Q8WWQ2 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-S3-AA15-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| HPSE2 | insertion | Nonsense_Mutation | novel | c.72_73insAAGAAAAGGTCTCAAACAACAAAGAGCTGAAAGGA | p.Gly25LysfsTer10 | p.G25Kfs*10 | Q8WWQ2 | protein_coding | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| HPSE2 | insertion | Frame_Shift_Ins | novel | c.70_71insAGTTACAAAAG | p.Pro24GlnfsTer30 | p.P24Qfs*30 | Q8WWQ2 | protein_coding | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| HPSE2 | SNV | Missense_Mutation | rs201787008 | c.1681C>T | p.Arg561Cys | p.R561C | Q8WWQ2 | protein_coding | deleterious(0) | possibly_damaging(0.548) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| HPSE2 | SNV | Missense_Mutation | novel | c.47N>G | p.Ser16Cys | p.S16C | Q8WWQ2 | protein_coding | deleterious_low_confidence(0.01) | benign(0.436) | TCGA-EA-A97N-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| HPSE2 | SNV | Missense_Mutation | c.174N>T | p.Lys58Asn | p.K58N | Q8WWQ2 | protein_coding | tolerated(0.1) | benign(0.146) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| HPSE2 | SNV | Missense_Mutation | rs778752620 | c.1349G>A | p.Arg450His | p.R450H | Q8WWQ2 | protein_coding | deleterious(0.04) | benign(0.007) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| HPSE2 | SNV | Missense_Mutation | c.272N>A | p.Gly91Asp | p.G91D | Q8WWQ2 | protein_coding | tolerated(0.56) | probably_damaging(0.998) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| HPSE2 | SNV | Missense_Mutation | rs767720704 | c.1691N>A | p.Arg564Gln | p.R564Q | Q8WWQ2 | protein_coding | tolerated(0.1) | probably_damaging(0.968) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |